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A previously fit 52-year-old man presented with severe progressive exertional dyspnea. He was in heart-failure with an elevated jugular-venous-pressure, edema, and increased plasma-NTpro-BNP levels of 4285 μg/mL (upper limit of normal <900 μg/mL). His ECG demonstrated sinus-rhythm with low limb and chest lead voltages ( Figure 1 ). He had significant proteinuria with renal and bone marrow biopsies confirming light-chain amyloidosis. Cardiac magnetic resonance imaging revealed concentric left-ventricular hypertrophy with an ejection fraction of 65%, left-ventricular end-diastolic volume of 146 mL, left-ventricular end-systolic volume of 51 mL, leftventricular mass of 245 g, and left-atrial volume of 144 mL ( At follow-up, 2.5 years later, his functional status had markedly improved and he was exercising regularly. His cardiovascular examination and plasma-NTpro-BNP level (117 μg/mL) was normal. His ECG showed some recovery of voltages in the limb leads ( Figure 5 ). Repeat cardiac magnetic resonance imaging showed minimal change in left-ventricular volumes, function, and mass (left-ventricular end-diastolic volume, 138 mL; left-ventricular end-systolic volume, 43mL; ejection fraction, 69%; left-ventricular mass, 235 g), although left atrial volume was significantly reduced (105 mL; Figure 6 , Movie I in the online-only Data Supplement). Late gadolinium-enhanced imaging demonstrated marked regression of the subendocardial hyperenhancement (Figures 7 and 8) .
Prognosis for patients with light-chain amyloid and cardiac infiltration has historically been dismal, and extensive cardiac involvement has generally been regarded as a contraindication to stem cell transplantation. [1] [2] [3] This case suggests that stem cell transplantation can lead to regression of cardiac amyloid and may be considered in selected patients.
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